Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Insights and Forecast to 2028

Report ID: 1240529 | Published Date: Jan 2025 | No. of Page: 86 | Base Year: 2024 | Rating: 4 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Exondys
        1.2.3 Emflaza
        1.2.4 Translarna
    1.3 Market by Application
        1.3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Hospitals
        1.3.3 Clinics
        1.3.4 Home Care
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Perspective (2017-2028)
    2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Growth Trends by Region
        2.2.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Region (2017-2022)
        2.2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Region (2023-2028)
    2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Dynamics
        2.3.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Trends
        2.3.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
        2.3.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
        2.3.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Revenue
        3.1.1 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Revenue (2017-2022)
        3.1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Players (2017-2022)
    3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue
    3.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Concentration Ratio
        3.4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in 2021
    3.5 Duchenne Muscular Dystrophy (DMD) Therapeutics Key Players Head office and Area Served
    3.6 Key Players Duchenne Muscular Dystrophy (DMD) Therapeutics Product Solution and Service
    3.7 Date of Enter into Duchenne Muscular Dystrophy (DMD) Therapeutics Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Duchenne Muscular Dystrophy (DMD) Therapeutics Breakdown Data by Type
    4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Type (2017-2022)
    4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Type (2023-2028)
5 Duchenne Muscular Dystrophy (DMD) Therapeutics Breakdown Data by Application
    5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Application (2017-2022)
    5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2017-2028)
    6.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
        6.2.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017-2022)
        6.2.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2023-2028)
        6.2.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type (2017-2028)
    6.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
        6.3.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017-2022)
        6.3.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2023-2028)
        6.3.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application (2017-2028)
    6.4 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
        6.4.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2017-2022)
        6.4.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2023-2028)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2017-2028)
    7.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
        7.2.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017-2022)
        7.2.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2023-2028)
        7.2.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type (2017-2028)
    7.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
        7.3.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017-2022)
        7.3.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2023-2028)
        7.3.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application (2017-2028)
    7.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
        7.4.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2017-2022)
        7.4.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2023-2028)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2017-2028)
    8.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
        8.2.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2023-2028)
        8.2.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type (2017-2028)
    8.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
        8.3.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2023-2028)
        8.3.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application (2017-2028)
    8.4 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region
        8.4.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2023-2028)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2017-2028)
    9.2 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
        9.2.1 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017-2022)
        9.2.2 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2023-2028)
        9.2.3 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type (2017-2028)
    9.3 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
        9.3.1 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017-2022)
        9.3.2 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2023-2028)
        9.3.3 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application (2017-2028)
    9.4 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
        9.4.1 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2017-2022)
        9.4.2 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2023-2028)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2017-2028)
    10.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
        10.2.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2023-2028)
        10.2.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type (2017-2028)
    10.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
        10.3.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2023-2028)
        10.3.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application (2017-2028)
    10.4 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
        10.4.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2023-2028)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 Sarepta Therapeutics
        11.1.1 Sarepta Therapeutics Company Details
        11.1.2 Sarepta Therapeutics Business Overview
        11.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
        11.1.4 Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
        11.1.5 Sarepta Therapeutics Recent Developments
    11.2 PTC Therapeutics
        11.2.1 PTC Therapeutics Company Details
        11.2.2 PTC Therapeutics Business Overview
        11.2.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
        11.2.4 PTC Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
        11.2.5 PTC Therapeutics Recent Developments
    11.3 Pfizer
        11.3.1 Pfizer Company Details
        11.3.2 Pfizer Business Overview
        11.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
        11.3.4 Pfizer Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
        11.3.5 Pfizer Recent Developments
    11.4 Bristol-Myers Squibb
        11.4.1 Bristol-Myers Squibb Company Details
        11.4.2 Bristol-Myers Squibb Business Overview
        11.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
        11.4.4 Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
        11.4.5 Bristol-Myers Squibb Recent Developments
    11.5 Italfarmaco
        11.5.1 Italfarmaco Company Details
        11.5.2 Italfarmaco Business Overview
        11.5.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
        11.5.4 Italfarmaco Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
        11.5.5 Italfarmaco Recent Developments
    11.6 Santhera Pharmaceuticals
        11.6.1 Santhera Pharmaceuticals Company Details
        11.6.2 Santhera Pharmaceuticals Business Overview
        11.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
        11.6.4 Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
        11.6.5 Santhera Pharmaceuticals Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer

List of Tables
    Table 1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of Exondys
    Table 3. Key Players of Emflaza
    Table 4. Key Players of Translarna
    Table 5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 6. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 7. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2017-2022) & (US$ Million)
    Table 8. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2017-2022)
    Table 9. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 10. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2023-2028)
    Table 11. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends
    Table 12. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
    Table 13. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
    Table 14. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
    Table 15. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Players (2017-2022) & (US$ Million)
    Table 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Players (2017-2022)
    Table 17. Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics as of 2021)
    Table 18. Ranking of Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Companies by Revenue (US$ Million) in 2021
    Table 19. Global 5 Largest Players Market Share by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (CR5 and HHI) & (2017-2022)
    Table 20. Key Players Headquarters and Area Served
    Table 21. Key Players Duchenne Muscular Dystrophy (DMD) Therapeutics Product Solution and Service
    Table 22. Date of Enter into Duchenne Muscular Dystrophy (DMD) Therapeutics Market
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
    Table 25. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2017-2022)
    Table 26. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 27. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2023-2028)
    Table 28. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
    Table 29. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Application (2017-2022)
    Table 30. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 31. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Application (2023-2028)
    Table 32. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
    Table 33. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2023-2028) & (US$ Million)
    Table 34. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
    Table 35. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2023-2028) & (US$ Million)
    Table 36. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 37. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 38. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
    Table 39. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2023-2028) & (US$ Million)
    Table 40. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
    Table 41. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2023-2028) & (US$ Million)
    Table 42. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 43. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 44. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
    Table 45. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2023-2028) & (US$ Million)
    Table 46. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
    Table 47. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2023-2028) & (US$ Million)
    Table 48. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2017-2022) & (US$ Million)
    Table 49. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2023-2028) & (US$ Million)
    Table 50. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
    Table 51. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2023-2028) & (US$ Million)
    Table 52. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
    Table 53. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2023-2028) & (US$ Million)
    Table 54. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 55. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 56. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
    Table 57. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2023-2028) & (US$ Million)
    Table 58. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
    Table 59. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2023-2028) & (US$ Million)
    Table 60. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 61. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 62. Sarepta Therapeutics Company Details
    Table 63. Sarepta Therapeutics Business Overview
    Table 64. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product
    Table 65. Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million)
    Table 66. Sarepta Therapeutics Recent Developments
    Table 67. PTC Therapeutics Company Details
    Table 68. PTC Therapeutics Business Overview
    Table 69. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product
    Table 70. PTC Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million)
    Table 71. PTC Therapeutics Recent Developments
    Table 72. Pfizer Company Details
    Table 73. Pfizer Business Overview
    Table 74. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product
    Table 75. Pfizer Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million)
    Table 76. Pfizer Recent Developments
    Table 77. Bristol-Myers Squibb Company Details
    Table 78. Bristol-Myers Squibb Business Overview
    Table 79. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product
    Table 80. Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million)
    Table 81. Bristol-Myers Squibb Recent Developments
    Table 82. Italfarmaco Company Details
    Table 83. Italfarmaco Business Overview
    Table 84. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product
    Table 85. Italfarmaco Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million)
    Table 86. Italfarmaco Recent Developments
    Table 87. Santhera Pharmaceuticals Company Details
    Table 88. Santhera Pharmaceuticals Business Overview
    Table 89. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product
    Table 90. Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022) & (US$ Million)
    Table 91. Santhera Pharmaceuticals Recent Developments
    Table 92. Research Programs/Design for This Report
    Table 93. Key Data Information from Secondary Sources
    Table 94. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type: 2021 VS 2028
    Figure 2. Exondys Features
    Figure 3. Emflaza Features
    Figure 4. Translarna Features
    Figure 5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application: 2021 VS 2028
    Figure 6. Hospitals Case Studies
    Figure 7. Clinics Case Studies
    Figure 8. Home Care Case Studies
    Figure 9. Duchenne Muscular Dystrophy (DMD) Therapeutics Report Years Considered
    Figure 10. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 11. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 12. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region: 2021 VS 2028
    Figure 13. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Players in 2021
    Figure 14. Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics as of 2021)
    Figure 15. The Top 10 and 5 Players Market Share by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in 2021
    Figure 16. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY (2017-2028) & (US$ Million)
    Figure 17. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Type (2017-2028)
    Figure 18. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Application (2017-2028)
    Figure 19. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share by Country (2017-2028)
    Figure 20. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 21. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 22. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY (2017-2028) & (US$ Million)
    Figure 23. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Type (2017-2028)
    Figure 24. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Application (2017-2028)
    Figure 25. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share by Country (2017-2028)
    Figure 26. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. U.K. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Nordic Countries Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY (2017-2028) & (US$ Million)
    Figure 33. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Type (2017-2028)
    Figure 34. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Application (2017-2028)
    Figure 35. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share by Region (2017-2028)
    Figure 36. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY (2017-2028) & (US$ Million)
    Figure 43. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Type (2017-2028)
    Figure 44. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Application (2017-2028)
    Figure 45. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share by Country (2017-2028)
    Figure 46. Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 47. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 48. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY (2017-2028) & (US$ Million)
    Figure 49. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Type (2017-2028)
    Figure 50. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share by Application (2017-2028)
    Figure 51. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share by Country (2017-2028)
    Figure 52. Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 53. Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 54. UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 55. Sarepta Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
    Figure 56. PTC Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
    Figure 57. Pfizer Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
    Figure 58. Bristol-Myers Squibb Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
    Figure 59. Italfarmaco Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
    Figure 60. Santhera Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2017-2022)
    Figure 61. Bottom-up and Top-down Approaches for This Report
    Figure 62. Data Triangulation
    Figure 63. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
Frequently Asked Questions
Duchenne Muscular Dystrophy (DMD) Therapeutics report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Duchenne Muscular Dystrophy (DMD) Therapeutics report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Duchenne Muscular Dystrophy (DMD) Therapeutics report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Ceiling Grid System

Ceiling Grid System market is segmented by Type and by Application. Players, stakeholders, and ot ... Read More